Chronic Spontaneous Urticaria: Second-Line Treatments Explained (2026 Guide)

Imagine scratching your skin until it bleeds, not because of a bee sting or a pollen flare-up, but for no reason at all. If you have Chronic Spontaneous Urticaria, also known as CSU, this is likely your reality. It is a persistent inflammatory skin condition where hives and swelling appear without any specific trigger for more than six weeks. About 60% to 80% of chronic urticaria cases fall into this category. For many, standard antihistamines just don't cut it. When first-line therapies fail, you need a plan B. This guide breaks down the second-line treatments available in 2026, helping you understand what works, who it works for, and what’s coming next.

When First-Line Therapy Fails

The journey usually starts with second-generation H1 antihistamines. These are the go-to drugs for most people because they are safe and non-drowsy. However, only about 40% of patients achieve significant symptom relief with standard doses. That leaves roughly 60% of people still suffering from painful hives and angioedema. Doctors often try increasing the dose up to four times the normal amount before declaring the treatment a failure. But even with higher doses, many patients hit a wall. This is where second-line treatments step in. The goal isn’t just to reduce symptoms slightly; it’s to get complete control over the disease so you can sleep through the night and live without constant itching.

Omalizumab: The Current Standard

For years, Omalizumab has been the gold standard for second-line therapy. It is a monoclonal antibody that targets IgE, the immune protein involved in allergic reactions. By binding to free IgE, it prevents mast cells from releasing histamine, which causes the hives. You receive it as a subcutaneous injection, typically 300 mg once a month. It works well for about 30% to 70% of patients who didn’t respond to antihistamines. However, it’s not a magic bullet. Around 70% of patients do not achieve complete disease control with omalizumab alone. It is particularly less effective for those with IgG-mediated autoimmune urticaria, a subtype affecting about 30% of CSU patients. If you’ve tried omalizumab and still see hives, you’re not alone, and there are other options on the horizon.

New Contenders: Dupilumab and Remibrutinib

The treatment landscape is shifting rapidly. Two new drugs have shown promising results in recent phase 3 clinical trials completed in 2024. Dupilumab is an anti-IL-4Rα antibody already approved for eczema and asthma. In trials for CSU, it achieved complete response rates of 30% to 31% at week 24. While these numbers are comparable to omalizumab, dupilumab offers a different mechanism of action that might help patients who didn’t respond to IgE-targeting therapies. Then there is Remibrutinib, a Bruton tyrosine kinase inhibitor (BTKi). This drug takes a unique approach by suppressing both mast cell and basophil degranulation while reducing autoantibody levels. In large trials involving nearly 1,000 adults, remibrutinib showed complete response rates of 28% to 32%. A major advantage here is convenience: remibrutinib is taken orally as a pill, whereas omalizumab requires monthly injections. This could significantly improve adherence for patients who dislike needles.

Cyclosporine: The Heavy Hitter

Before biologics became common, Cyclosporine was often used as a third-line option. It remains relevant today, especially for patients with autoimmune CSU who don’t respond to omalizumab. Studies show it improves symptoms in 54% to 73% of these difficult-to-treat cases. However, cyclosporine is a potent immunosuppressant with serious side effects, including kidney dysfunction and high blood pressure. Because of these risks, doctors usually reserve it for severe cases where newer biologics have failed or aren’t accessible. It requires careful monitoring of blood pressure and kidney function, making it a commitment rather than a quick fix.

Why Some Treatments Fail: Understanding Subtypes

Not all CSU is created equal. Experts like Dr. Marcus Maurer emphasize that identifying autoimmune endotypes is critical. About 40% to 50% of CSU cases involve mast cell-activating IgE and/or IgG autoantibodies. If your hives are driven by IgG autoantibodies, omalizumab may not work well because it only targets IgE. This explains why some patients feel frustrated after trying the "standard" second-line treatment. The future of CSU care lies in personalized medicine. Within the next few years, doctors may be able to test for specific antibodies to predict whether you’ll respond better to omalizumab, dupilumab, or a BTK inhibitor like remibrutinib. Until then, trial and error remains part of the process.

Safety and Development Challenges

Developing new treatments for CSU is tricky. Not every drug makes it to market. For example, fenebrutinib, another BTK inhibitor, had its CSU program discontinued due to off-target effects causing liver enzyme elevation in some patients. This highlights the importance of safety monitoring. While remibrutinib and dupilumab look promising, long-term data is still being collected. Patients should discuss potential side effects thoroughly with their allergists or dermatologists. For instance, while oral pills are convenient, they require daily adherence and may interact with other medications. Injections, while less frequent, carry risks of injection site reactions. Understanding these trade-offs helps set realistic expectations.

What To Do Next

If you are struggling with CSU despite taking antihistamines, don’t give up. Talk to your specialist about escalating to second-line therapy. Ask if omalizumab is right for you, or if you might benefit from emerging options like dupilumab or remibrutinib, depending on availability and approval status in your region. Keep a symptom diary to track your response. Note when hives appear, how severe they are, and any potential triggers, even if they seem unrelated. This data helps your doctor tailor your treatment. Remember, finding the right medication can take time, but complete control is possible for many patients.